Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
04 2020
Historique:
received: 14 05 2019
accepted: 21 02 2020
revised: 10 02 2020
pubmed: 7 3 2020
medline: 1 12 2020
entrez: 7 3 2020
Statut: ppublish

Résumé

Fatty acid synthase (FASN) is commonly overexpressed in prostate cancer and associated with tumour progression. FASN is responsible for de novo synthesis of the fatty acid palmitate; the building block for protein palmitoylation. Recent work has suggested that alongside its established role in promoting cell proliferation FASN may also promote invasion. We now find depletion of FASN expression increases prostate cancer cell adhesiveness, impairs HGF-mediated cell migration and reduces 3D invasion. These changes in motility suggest that FASN can mediate actin cytoskeletal remodelling; a process known to be downstream of Rho family GTPases. Here, we demonstrate that modulation of FASN expression specifically impacts on the palmitoylation of the atypical GTPase RhoU. Impaired RhoU activity in FASN depleted cells leads to reduced adhesion turnover downstream of paxillin serine phosphorylation, which is rescued by addition of exogenous palmitate. Moreover, canonical Cdc42 expression is dependent on the palmitoylation status of RhoU. Thus we uncover a novel relationship between FASN, RhoU and Cdc42 that directly influences cell migration potential. These results provide compelling evidence that FASN activity directly promotes cell migration and supports FASN as a potential therapeutic target in metastatic prostate cancer.

Identifiants

pubmed: 32139877
doi: 10.1038/s41388-020-1243-2
pii: 10.1038/s41388-020-1243-2
pmc: PMC7190568
doi:

Substances chimiques

FASN protein, human EC 2.3.1.85
Fatty Acid Synthase, Type I EC 2.3.1.85
RHOU protein, human EC 3.6.1.-
cdc42 GTP-Binding Protein EC 3.6.5.2
rho GTP-Binding Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3666-3679

Références

American Cancer Society. Survival rates for prostate cancer. American Cancer Society; 2016. http://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html#references .
Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: molecular insights and future challenges. J Carcinog. 2012;11:4.
doi: 10.4103/1477-3163.93001
Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–74.
doi: 10.1038/nrc1075
Lawson CD, Ridley AJ. Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol. 2017;2.
Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6:1353–63.
doi: 10.1242/dmm.011338
Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6:551–62.
doi: 10.2217/fon.10.11
Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19–22.
doi: 10.1002/ijc.10127
Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol. 2005;206:214–9.
doi: 10.1002/path.1760
Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther. 2009;8:214–24.
doi: 10.1158/1535-7163.MCT-08-0722
Li N, Bu X, Tian X, Wu P, Yang L, Huang P. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. Nutr Cancer. 2012;64:864–70.
doi: 10.1080/01635581.2012.701704
Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. Mol Carcinog. 2016;55:2278–90.
doi: 10.1002/mc.22468
Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541:41–5.
doi: 10.1038/nature20791
Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997;57:995–1002.
pubmed: 9041206
Whale AD, Dart A, Holt M, Jones GE, Wells CM. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene. 2013;32:2114–20.
doi: 10.1038/onc.2012.233
Dart AE, Box GM, Court W, Gale ME, Brown JP, Pinder SE, et al. PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion. J Cell Biol. 2015;211:863–79.
doi: 10.1083/jcb.201501072
Hodge RG, Ridley AJ. Regulation and functions of RhoU and RhoV. Small GTPases. 2017;1:1–8.
Berzat AC, Buss JE, Chenette EJ, Weinbaum CA, Shutes A, Der CJ, et al. Transforming activity of the Rho family GTPase, Wrch-1, a Wnt-regulated Cdc42 homolog, is dependent on a novel carboxyl-terminal palmitoylation motif. J Biol Chem. 2005;280:33055–65.
doi: 10.1074/jbc.M507362200
Czuchra A, Wu X, Meyer H, van Hengel J, Schroeder T, Geffers R, et al. Cdc42 is not essential for filopodium formation, directed migration, cell polarization, and mitosis in fibroblastoid cells. Mol Biol Cell. 2005;16:4473–84.
doi: 10.1091/mbc.e05-01-0061
Zhang B, Zheng Y. Negative regulation of Rho family GTPases Cdc42 and Rac2 by homodimer formation. J Biol Chem. 1998;273:25728–33.
doi: 10.1074/jbc.273.40.25728
Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H, et al. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncologica. 2018;57:187–94.
doi: 10.1080/0284186X.2017.1337926
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.
doi: 10.1038/nrc2222
Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2019;116:631–40.
doi: 10.1073/pnas.1808834116
Alinezhad S, Vaananen RM, Mattsson J, Li Y, Tallgren T, Tong Ochoa N, et al. Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PLoS ONE. 2016;11:e0155901.
doi: 10.1371/journal.pone.0155901
Reymond N, Im JH, Garg R, Vega FM, Borda d’Agua B, Riou P, et al. Cdc42 promotes transendothelial migration of cancer cells through beta1 integrin. J Cell Biol. 2012;199:653–68.
doi: 10.1083/jcb.201205169
De Piano M, Jones GE, Wells CM. Live cell imaging: tracking cell movement. In: Standard and super‐resolution bioimaging data analysis: a primer. 2017. Chapter 7. p. 173–200. Wiley.
Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012;63.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
doi: 10.1126/science.1260419
NC. I. The Cancer Genome Atlas. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga .
Team RC. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. https://www.R-project.org/ .

Auteurs

Mario De Piano (M)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Valeria Manuelli (V)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Giorgia Zadra (G)

Departments of Oncologic Pathology and Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Jonathan Otte (J)

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Per-Henrik D Edqvist (PD)

Department of Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden.

Fredrik Pontén (F)

Department of Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden.

Salpie Nowinski (S)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Athanasios Niaouris (A)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Anita Grigoriadis (A)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Massimo Loda (M)

Departments of Oncologic Pathology and Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, USA.

Mieke Van Hemelrijck (M)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK.

Claire M Wells (CM)

School of Cancer and Pharmaceutical Sciences, Kings College London, London, SE1 1UL, UK. claire.wells@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH